Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

RE-SPECT CVT: a Randomised, Open-label, Exploratory Trial With Blinded Endpoint Adjudication (PROBE), Comparing Efficacy and Safety of Oral Dabigatran Etexilate Versus Oral Warfarin in Patients With Cerebral Venous and Dural Sinus Thrombosis Over a 24-week Period

NCT02913326 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT02913326
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02913326 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
RE-SPECT CVT: a Randomised, Open-label, Exploratory Trial With Blinded Endpoint Adjudication (PROBE), Comparing Efficacy and Safety of Oral Dabigatran Etexilate Versus Oral Warfarin in Patients With Cerebral Venous and Dural Sinus Thrombosis Over a 24-week Period
Lead sponsor
Boehringer Ingelheim
Phase
Phase 3
Overall status
Completed
Start date
December 13, 2016
Completion date
June 22, 2018
Enrollment
120 (actual)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

thromboembolism